IARC: Nearly 1M Gastric Cancer Cases in 2024, 760K Linked to H. pylori
Nearly 1 million people developed gastric cancer worldwide in 2024, yet roughly 760,000 cases were attributable to a bacterial infection that can be cured with antibiotics.
The International Agency for Research on Cancer (IARC) released the estimates on Nov. 3 for Gastric Cancer Awareness Month, ranking the disease as the fifth most common cancer and the fifth leading cause of cancer death globally, Oncodaily reported. Nearly 650,000 people died from the disease in 2024, and almost two-thirds of cases and deaths occurred among men.
Geography drives the disparity
Asia bears the greatest burden, with China alone accounting for more than one-third of global cases and deaths. The figures reflect substantial differences in gastric cancer burden between populations and reinforce the importance of prevention strategies adapted to local epidemiology, IARC said.
Helicobacter pylori: a preventable cause
Helicobacter pylori is a spiral-shaped bacterium that infects the stomach lining and is recognized by IARC as a Group 1 carcinogen. Persistent infection can cause chronic inflammation that gradually damages the stomach lining, leading some individuals through a series of precancerous changes known as the Correa cascade: chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and eventually gastric adenocarcinoma.
Most people with H. pylori never develop gastric cancer. The likelihood of progression depends on bacterial virulence, genetic susceptibility, environmental exposures, and the extent of existing damage to the gastric mucosa. Eradication of the infection can also lead to regression in selected cases of localized H. pylori-positive gastric MALT lymphoma.
Symptoms often mimic common ailments
Early-stage disease may produce few or no symptoms. When symptoms develop, they may resemble common gastrointestinal conditions, making early detection challenging.
Dr. Rajesh Mistry, Senior Director of Oncology at Kokilaben Dhirubhai Ambani Hospital in Mumbai, said people should pay attention to digestive changes that persist rather than repeatedly treating them as routine acidity. “Feeling full after eating very little is known as early satiety,” he told Firstpost.
According to Dr. Vishnu Hari, Associate Director and Head of Medical Oncology at Sarvodaya Hospital in Faridabad, recurring indigestion or heartburn — particularly when paired with upper abdominal discomfort — could signal a deeper stomach issue if standard remedies fail to help.
Unexplained fatigue and weakness may result from anemia caused by slow bleeding in the stomach. Black, tarry stools can also indicate bleeding in the digestive tract. Difficulty swallowing, or dysphagia, can occur when a tumor near the junction of the stomach and esophagus interferes with the passage of food.
“Stomach cancer can be difficult to spot early because its symptoms often resemble everyday problems such as acidity and indigestion,” Dr. Hari told Firstpost. “A change in digestion that lingers or feels unusual should not be ignored.”
Diagnosis and the screening gap
Upper gastrointestinal endoscopy with biopsy is central to establishing a diagnosis when gastric cancer is suspected. Biomarker testing for HER2, PD-L1, MSI/dMMR, and CLDN18.2 may help guide treatment decisions when clinically appropriate.
Urea breath tests, stool antigen tests, and biopsy-based methods can detect H. pylori* infection, though testing positive does not mean a patient has stomach cancer. Screening strategies must consider individual risk, regional disease burden, and the available evidence.
November also marks Lung Cancer Awareness Month and Pancreatic Cancer Awareness Month. While these cancers vary in their biology, risk factors, and treatment methods, they all face a pressing need for earlier detection, ongoing scientific advancement, and better outcomes for patients.